Clinically, the treatment and prognosis of breast cancer are largely determined by its molecular subtype, which is defined by the expression profiles of human epidermal growth factor receptor 2 (HER2) and hormone receptors (Prat et al., 2010; Perou et al., 2000). This evidence concerns the gene ERBB2 and breast carcinoma.